MOTS-C

Comparing MOTS-C Unit Costs When Proposals Contain Different Items

Comparing MOTS-C Unit Costs When Proposals Contain Different Items – Evora research guide

A unit-cost comparison can become misleading when one proposal contains a single item and another contains a bundle or several presentations. The buyer needs to decide which costs and quantities belong together before comparing the figures. A common unit alone does not make unlike proposals equivalent.

An enquiry about “MOTS-C price per mg” should therefore identify the structure of each offer. This guide covers allocation and comparison questions in research purchasing. It does not verify an active bundle, a material amount or a particular commercial saving.

Describe each proposal before reducing it to a number

The organisation should record what each offer actually contains. Additional items, different presentations and separate commercial conditions should remain visible. A short summary can help the approver understand why the proposals may not be directly comparable.

The buyer should resist assigning all apparent value to the item of greatest interest. If another component is included, its role in the cost comparison needs an understandable basis. An attractive average should not replace a truthful description of the purchase.

Identify the quantity that belongs to the selected item

The denominator should concern the relevant material, rather than the combined weight or quantity of unrelated components. If the description does not establish that amount, the record should remain incomplete until clarification is obtained.

The organisation should not copy a quantity from another seller's page to complete the calculation. Similar names or a familiar presentation do not authenticate the candidate's contents. A purchasing metric is only as defensible as the information assigned to its inputs.

Explain any allocation rule used

Where a combined price must be allocated, the method should be stated rather than hidden. The organisation may need additional commercial information before a defensible comparison is possible. A proportional split chosen for convenience should not be presented as a seller's confirmed item price.

If no reasonable allocation basis is available, the buyer can compare proposal totals while flagging that a component-level figure has not been established. This preserves useful financial information without inventing precision.

Request a quotation on a comparable basis

The KLIKMOTS-C reference for a comparable quotation request can identify the candidate in a commercial enquiry.

The buyer can ask for information about the actual proposal it wishes to compare. A clearly defined request may resolve ambiguity more efficiently than trying to reverse-engineer an item price from unrelated promotional material.

Keep financial allocation separate from scientific equivalence

Even a defensible cost allocation does not establish that two presentations are interchangeable for a project. The responsible researcher should assess the relevant characteristics. Purchasing staff should not use a favourable unit figure to settle a technical question.

The same caution applies to additional items that the organisation does not need. Their inclusion may affect the total cost without adding value to the approved requirement. The approval note should distinguish a larger offering from a better fit for the project.

Present the comparison with its limits intact

The closing note should identify which figures are directly comparable and which depend on an allocation assumption. Any unresolved quantity or cost component should remain visible. The approver can then decide whether clarification, a revised proposal or no further action is appropriate.

This approach makes unit-cost analysis more honest and useful. It can support a focused commercial enquiry without manufacturing a saving or implying that an economical proposal is scientifically superior. No calculation in this guide establishes treatment effectiveness, clinical safety or permission for human administration, and no product-specific dose or preparation advice is supplied.

EvoraCare product information

For current product specifications and availability, see the MOTS-C product page.

Related productSee the product page, lab report and batch details.
View product

More on this topic: MOTS-C articles · Lab reports (COAs) · All products

This article is for general educational purposes and describes laboratory research. It is not medical advice.

Keep reading